425
Views
149
CrossRef citations to date
0
Altmetric
Original Article

Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease

, , &
Pages 496-502 | Received 07 Mar 2012, Accepted 01 May 2012, Published online: 02 Jan 2014

REFERENCES

  • Pearson CM. Polymyositis and dermatomyositis. In: McCarty DJ, editor. Arthritis and allied condition. 9th ed. Philadelphia: Lea and Febiger; 1979. p. 742.
  • Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermato-myopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.
  • Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80: 329–32.
  • High WA, Cohen JB, Murphy BA, Costner MI. Fatal interstitial pulmonary fibrosis in anti-Jo- 1-negative amyopathic dermato-myositis. J Am Acad Dermatol. 2003;49:295–8.
  • Neuhaus IM, Connolly MK. An unusual presentation of amyo-pathic dermatomyositis associated with fatal interstitial lung disease. Arch Dermatol. 2006;142:113–4.
  • Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyo-sitis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462–7.
  • Chow SK, Yeap SS. Amyopathic dermatomyositis and pulmon-ary fibrosis. Clin Rheumatol. 2000;19:484–5.
  • Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21:391–6.
  • Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermato-myositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44:1282–6.
  • Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermat-omyositis. Eur Respir J. 2006;28:1005–12.
  • Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid pro-gressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647–54.
  • Ideura G, Hanaoka M, Koizumi T, Fujimoto K, Shimojima Y, Ishii W, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007;101: 1406–11.
  • Nagatomo Y, Okayama A, Murai K, Sasaki T, Kuroki M, Tanaka G, et al. Successful treatment using high-dose intravenous immunoglobulin in a patient with rapidly progressive interstitial pneumonia associated with dermatomyositis. Mod Rheumatol. 2000;10:165–8.
  • Miyake S, Ohtani Y, Sawada M, Inase N, Miyazaki Y, Takano S, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vase Diffuse Lung Dis. 2002;19:128–33.
  • Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno 0, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26:436–9.
  • Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto H, Sakamoto N, et al. Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med. 2008;47:785–90.
  • Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibody to a 140-kd polypeptide, CADM-140, in Japa-nese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.
  • Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyo-pathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193–200.
  • Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermato-myositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2011 (Epub ahead of print).
  • Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthe-tases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol. 1990;144:1737–43.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344.
  • ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a longterm, prospective study. Arthritis Rheum. 1990;33:634–43.
  • Ham BH. Antibodies to DNA. N Engl J Med. 1998;338:1359–68.
  • Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum fenitin correlates with activity of anti-MDA5 anti-body-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011; 21:223–7 (Epub 2010 Nov 5).
  • Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2011 (Epub ahead of print).
  • Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380–7.
  • Fiorentino D, Chung L, Zwemer J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibody to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65: 25–34.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.